Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan

Oncology
N ZirasV Georgoulias

Abstract

To evaluate the efficacy and tolerance of the gemcitabine/oxaliplatin (GEMOX) combination as second-line chemotherapy for patients with advanced colorectal cancer (CRC) pretreated with an irinotecan (CPT-11)/5-fluorouracil (5-FU)/leucovorin (LV) regimen. Patients with documented disease progression during or after first-line treatment with CPT-11 and 5-FU/LV were enrolled. Gemcitabine (1,000 mg/m(2) days 1 and 8) and oxaliplatin (100 mg/m(2) day 1) were administered every 3 weeks. Partial responses were observed in 6 of the 34 (17.7%) patients enrolled (intention-to-treat analysis; overall response rate: 17.7%; 95% confidence interval 4.8-30.5%). Eight (23.5%) patients experienced disease stabilization and 20 (59%) disease progression (tumor growth control rate = 41.2%). The median duration of response was 5.5 months, and the median time to tumor progression 2.7 months. The median overall survival was 9.1 months (1-year survival rate: 44.0%). Grade 3 neutropenia and thrombocytopenia occurred in 18 and 15% of the patients, respectively. Other severe non-hematologic toxicities were rare. The interesting tumor growth control rate and the favorable toxicity profile of the GEMOX regimen in pretreated patients with advanced CRC stron...Continue Reading

References

Nov 11, 1992·Investigational New Drugs·D F MooreJ L Abbruzzese
Jan 1, 1981·Cancer·A B MillerA Winkler
Aug 17, 1993·Biochemical Pharmacology·V W Ruiz van HaperenG J Peters
Feb 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A de GramontM Krulik
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Meta-analysis Group In CancerE Levy
May 30, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Díaz-RubioM Homerin
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y BécouarnP Rougier
Jul 23, 1999·Current Opinion in Oncology·M E Royce, R Pazdur
Oct 6, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C H KoehneD J Kerr
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E WassermanE Cvitkovic
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S GiacchettiF Lévi
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Aug 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S FaivreE Raymond
Feb 4, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D MavroudisV Georgoulias
Feb 11, 2003·American Journal of Clinical Oncology·Alfonso Dueñas-GonzálezJaime de la Garza
Mar 22, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S R AlbertsJ A Mailliard
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Werner ScheithauerDieter Depisch
Nov 12, 2003·Clinical Lung Cancer·Wolfgang SchutteReiner Bonner
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Jan 24, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Paolo BidoliEmilio Bajetta
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PectasidesD Skarlos
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jim CassidyEduardo Díaz-Rubio
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T AndréUNKNOWN GERCOR Group
Jan 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ki Young ChungLeonard B Saltz

❮ Previous
Next ❯

Citations

Oct 5, 2010·Metal-based Drugs·Nektaria MakriliaMuhammad Wasif Saif
Feb 19, 2008·Clinical Colorectal Cancer·David J Gallagher, Nancy Kemeny
Dec 1, 2010·Asia-Pacific Journal of Clinical Oncology·Eun Joo KangYeul Hong Kim
Dec 14, 2011·Asia-Pacific Journal of Clinical Oncology·Paul L MitchellMatthew Links
Dec 3, 2010·Journal of Chemotherapy·F Meriggi, A Zaniboni
Jan 12, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J RodriguezJ Garcia-Foncillas
Nov 4, 2008·Critical Reviews in Oncology/hematology·Jaume CapdevilaJosep Tabernero

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.